Replies to post #148 on Sio Gene Therapies Inc (fka SIOX)

[georgejjl]

Cohort 3 should be AMAZING with 3X the TU of Cohort 2

Volume Expansion
Cohort 3
4.2 x 107 TU
1800 µL total infusion volume

Gating item for filing
> Developing reliable, suspension-based manufacturing process
> Oxford Biomedica has initiated the manufacture of GMP batches
using this process

Oxford BioMedica should have capacity soon now that the Oxford/Astrazeneca vaccine production may be taking up less capacity at Oxford BioMedica.

Good luck and GOD bless,